pravastatin

pravastatin
Name	Pravastatin
Caption	Chemical structure of pravastatin
Tradename	Various
Routes of administration	Oral
Class	HMG-CoA reductase inhibitor
Legal status	Varies by country
Bioavailability	~17%
Protein bound	~50%
Metabolism	Minimal hepatic CYP450 metabolism
Elimination half-life	1.3–2.8 hours
Excretion	Urine and feces

pravastatin

Pravastatin is a lipid-lowering medication belonging to the statin class used to reduce low-density lipoprotein cholesterol and cardiovascular risk. It is prescribed for primary and secondary prevention of atherosclerotic events and for certain dyslipidemias in adults and children, often alongside lifestyle interventions. Clinical deployment of pravastatin involves coordination with cardiology, endocrinology, and public health strategies to reduce morbidity from ischemic heart disease and stroke.

Medical uses

Pravastatin is indicated to lower low-density lipoprotein cholesterol in patients with hypercholesterolemia and mixed dyslipidemia and to reduce the risk of myocardial infarction, stroke, and coronary revascularization. Guidelines from organizations such as the American College of Cardiology, the American Heart Association, and the European Society of Cardiology include statins among first-line therapies for primary prevention in at-risk populations and secondary prevention after acute coronary syndromes managed by teams including European Medicines Agency-regulated services and national healthcare systems like the National Health Service (England). Pediatric indications approved by regulators are based on evidence from trials often coordinated with centers such as Boston Children's Hospital and Great Ormond Street Hospital for children with familial hypercholesterolemia. In secondary prevention, pravastatin is used following interventions such as percutaneous coronary intervention performed in catheterization laboratories under guidance from groups like the American College of Cardiology Foundation.

Pharmacology

Pravastatin inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, reducing hepatic cholesterol synthesis and upregulating hepatic LDL receptors to enhance clearance of circulating LDL particles. Its pharmacokinetic profile—oral absorption, partial hepatic uptake via transporter proteins studied at institutions like the National Institutes of Health, and limited CYP450 metabolism compared with other statins—affects drug selection in patients managed by specialists at centers such as Mayo Clinic and Cleveland Clinic. Clinical pharmacology studies often reference methodology established at universities like Harvard University and Johns Hopkins University. Pravastatin's hydrophilicity and renal excretion pathways are relevant to dosing adjustments in patients seen in nephrology services at hospitals including Massachusetts General Hospital.

Adverse effects

Common adverse effects include myalgia, headache, and gastrointestinal symptoms reported in clinical trial cohorts overseen by academic centers such as Stanford University and University of Oxford. Less common but serious adverse events include rhabdomyolysis and hepatotoxicity, monitored in pharmacovigilance programs coordinated by regulatory bodies like the Food and Drug Administration and the European Medicines Agency. Neurocognitive complaints and new-onset diabetes mellitus have been observed in post-marketing surveillance data aggregated by organizations such as the World Health Organization. Management of adverse effects often involves multidisciplinary input from specialists affiliated with institutions like UCLA Health and Toronto General Hospital.

Interactions

Pravastatin has a lower propensity for CYP3A4-mediated drug–drug interactions than some other statins, making it a frequent choice when patients are prescribed agents metabolized by enzymes characterized in pharmacology texts from University of Cambridge and Yale University. Concomitant use with fibrates, azole antifungals promoted in formularies of hospitals such as Mount Sinai Hospital, or protease inhibitors used in HIV clinics like those at Amsterdam University Medical Centers may increase the risk of myopathy and requires specialist review. Drug interaction resources maintained by the British Pharmacopoeia and national formularies aid clinicians in hospitals such as St Thomas' Hospital when reconciling medications during admissions.

Contraindications and precautions

Pravastatin is contraindicated in pregnancy and lactation due to teratogenic risk and interference with fetal cholesterol synthesis, with guidance issued by agencies such as the Centers for Disease Control and Prevention and the American College of Obstetricians and Gynecologists. Active liver disease and unexplained persistent elevations of hepatic transaminases are contraindications noted in product labeling regulated by agencies including the European Medicines Agency. Caution is advised in patients with renal impairment managed by nephrology services at institutions like Johns Hopkins Hospital, and dose adjustments or alternative therapies are considered in consultation with specialists from networks such as the American Society of Nephrology.

History and society

Pravastatin was developed following the discovery of HMG-CoA reductase inhibition and the development of the statin class, a process involving academic and pharmaceutical collaborations similar to historical partnerships between universities like University of Tokyo and companies regulated by authorities such as the United States Food and Drug Administration. Its introduction influenced clinical practice guidelines promulgated by organizations including the World Heart Federation and impacted public health initiatives addressing cardiovascular disease promoted by the World Health Organization. Patent, marketing, and generic availability issues involved multinational corporations and legal frameworks centered on courts like the United States Court of Appeals and regulatory decisions by the European Commission. Cost and access considerations for pravastatin have been addressed in health policy analyses by institutions such as the Brookings Institution and The Lancet-affiliated research networks.

Category:Statins